• $5.1M
    Market Cap
  • -84.82%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Income Statement
Total Operating Revenue
N/A
N/A
7.8M
+6.96%
7.3M
+20.21%
6.1M
+17.45%
Cost of Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Gross Profit
0
-100.00%
7.8M
+6.96%
7.3M
+20.21%
6.1M
+17.45%
Sales and Marketing Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Research and Development Expense
-38,000
-99.47%
-7.2M
-53.82%
-15.5M
-14.92%
-18.2M
+18.58%
Depreciation and Amortization Expense
N/A
N/A
106,000
-20.90%
134,000
-17.28%
162,000
-4.14%
Total Operating Expenses
5.2M
-70.58%
17.6M
-20.28%
22.0M
-11.91%
25.0M
-1.26%
Operating Profit
-5.2M
-47.06%
-9.8M
-33.77%
-14.7M
-22.20%
-18.9M
-6.05%
Interest Income
144,000
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Income and Expense and Net
144,000
N/A
0
N/A
0
N/A
0
N/A
Total Nonoperating Income and Expense
7,000
-96.57%
204,000
-67.04%
619,000
+457.66%
111,000
+2,875.00%
Income before Taxes
-5.2M
-47.06%
-9.8M
-33.77%
-14.7M
-21.75%
-18.8M
-19.39%
Income Taxes
0
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Extraordinary Items
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
N/A
N/A
N/A
N/A
-14.1M
-25.03%
-18.8M
-6.62%
Net Income from Continuing Operations Applicable to Common
N/A
N/A
N/A
N/A
-14.1M
-25.03%
-18.8M
-19.39%
Basic EPS and Net Income
-1.41
-46.18%
-2.62
-32.30%
-3.87
-29.12%
-5.46
-36.73%
Diluted EPS and Net Income
-1.41
-46.18%
-2.62
-32.30%
-3.87
-29.12%
-5.46
-36.73%
Basic Weighted Average Shares
3.7M
0.00%
3.7M
-99.90%
3.7B
+105,823.08%
3.4M
+27.29%
Diluted Weighted Average Shares
3.7M
0.00%
3.7M
-99.90%
3.7B
+105,823.08%
3.4M
+27.29%
Balance Sheet
Cash and Cash Equivalents
4.1M
-57.06%
9.5M
-50.34%
19.2M
-46.19%
35.6M
-33.83%
Short-Term Investments
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
4.1M
-57.06%
9.5M
-50.34%
19.2M
-46.19%
35.6M
-33.83%
Total Current Assets
4.1M
-58.38%
9.9M
-52.41%
20.8M
-45.36%
38.1M
-30.36%
Accumulated Depreciation
N/A
N/A
N/A
N/A
1.7M
-36.83%
2.7M
+4.09%
Property and Plant and Equipment and Net
N/A
N/A
N/A
N/A
1.2M
+392.77%
235,000
-26.79%
Total Long-Term Assets
N/A
N/A
13,000
-92.61%
176,000
-54.76%
389,000
+21.18%
Total Assets
4.1M
-58.37%
9.9M
-70.72%
34.0M
-17.08%
41.0M
-30.37%
Income Taxes Payable
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Short-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Current Liabilities
329,000
-64.59%
929,000
-76.23%
3.9M
-22.16%
5.0M
+13.06%
Total Long-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Liabilities
N/A
N/A
67,000
-99.44%
12.1M
+149.98%
4.8M
-30.38%
Total Liabilities
329,000
-66.97%
996,000
-93.76%
16.0M
+62.16%
9.8M
-13.41%
Retained Earnings
-302.3M
+1.74%
-297.2M
+3.32%
-287.6M
+5.16%
-273.5M
+7.40%
Total Stockholders Equity
N/A
N/A
N/A
N/A
18.0M
-42.16%
31.1M
-34.44%
Total Shares Outstanding
3.7M
0.00%
3.7M
0.00%
3.7M
+0.36%
3.6M
+12.95%
Cash Flow
Cash from Operating Activities
-5.4M
-49.30%
-10.7M
-32.96%
-16.0M
-17.42%
-19.4M
-1.88%
Capital Expenditures
N/A
N/A
398,000
-41.12%
676,000
+686.05%
86,000
-40.28%
Cash from Investing Activities
N/A
N/A
-398,000
-41.12%
-676,000
+686.05%
-86,000
-40.28%
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
N/A
N/A
N/A
N/A
53,000
-95.69%
1.2M
-97.17%
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Operating Margin
N/A
N/A
-125.07%
-38.08%
-201.97%
-35.28%
-312.09%
-20.01%
Return on Assets
N/A
N/A
N/A
N/A
-37.70%
-0.15%
-37.76%
-9.22%
Return on Equity
N/A
N/A
N/A
N/A
-57.51%
+19.94%
-47.95%
-16.09%
Revenue Growth
N/A
N/A
6.96%
-65.56%
20.21%
+15.82%
17.45%
+129.53%
Current Ratio
12.55
+17.53%
10.68
+100.26%
5.33
-29.80%
7.60
-38.40%
Cash Ratio
12.43
+21.24%
10.25
+108.95%
4.90
-30.86%
7.09
-41.47%
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow